DEVELOPMENT VS COMMERCIAL OUTSOURCED MANUFACTURING PRACTICES: SMALL MOLECULEJ U N E , 2 0 1 7
P R E V I E W O F
DEVE
LOPM
ENT V
S COM
MERICAL OUTSOURCED MANUFACURING PRACTICES
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
2
Associate 16%
Director 31%
Vice President 8%
C-level 14%
Manager 27%
President 4%
Large (R&D $1B or more), 22%
Small (R&D less than $100M), 45%
Mid-size (R&D $100M-$999M), 34%
RESPONDENT LOCATION
NORTHAMERICA
71%
EUROPE25% ASIA AND
OTHER4%
JOBTITLE
COMPANYTYPE
*by o�ce location
Associate 16%
Director 31%
Vice President 8%
C-level 14%
Manager 27%
President 4%
Large (R&D $1B or more), 22%
Small (R&D less than $100M), 45%
Mid-size (R&D $100M-$999M), 34%
RESPONDENT LOCATION
NORTHAMERICA
71%
EUROPE25% ASIA AND
OTHER4%
JOBTITLE
COMPANYTYPE
*by o�ce location
CMOs continue to expand their service offerings to include spe-cialized development capabilities, especially contract manufac-turers with strengths in formulating poorly soluble compounds. Formulation development, analytical development and character-ization, clinical trial manufacturing and commercial manufactur-ing for drug substance and drug product may be obtained from a single provider with end-to-end services. Knowing whether this is the best approach for your organization is challenging. This re-port dives into how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership. Readers will gain insight into four different outsourc-ing scenarios for small molecule drugs enabling them to make more educated purchases of CMO services based on their unique needs. CMOs will gain a better understanding of customers’ re-quirements and how they change as a compound moves through the development to commercialization process.
D A T A C O L L E C T I O N I N Q 4 , 2 0 1 6
3 0 - M I N U T E , W E B - B A S E D
Q U A N T I T A T I V E S U R V E Y
REPORT OVERVIEW
1 9 4 R E S P O N D E N T S
MAJOR TOPICS:1. Outsourcing Philosophies
and Practices
2. CMO Perceptions and Interactions
3. CMO Selection Drivers
4. Study Data
Full Table of Contents on next page.
What you will learn:
2To learn more: contact us at [email protected] or +1(919)301-0106
DRUG DEVELOPERS
CONTRACT MANUFACTURERS
• Differences in CMO engagement and usage patterns based on outsourcing stage and internal capabilities and/or capacity
• Key differences in CMO selection drivers based on four different outsourcing scenarios: development-stage API manufacturing, commercial API manufacturing, development-stage drug product manufacturing and commercial drug product manufacturing
• Learn which CMO attributes are becoming more important to different types of outsourcing peers in order to gain advantages from their experiences
• Ways to improve your company’s sales and marketing strategies to specifically address the needs of different customer bases, as identified in CMO selection criteria, during specific decision-making scenarios
• Outsourcing propensity of the different buyers of outsourced services for both drug substance and drug product manufacturing
• How CMO awareness, familiarity, leadership, proposal volume, use and preference vary between outsourcers of development-stage or commercial-scale manufacturing in order to target specific audiences with the precise information they need
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
3
COPYRIGHT AND USAGE GUIDE
INTRODUCTION
METHODOLOGY
Participant Criteria
Respondent Demographics
4 Major Sections
OUTSOURCING PHILOSOPHIES AND PRACTICES
Primary Section Takeaways
Outsourcing Drivers—Small Molecule API
Outsourcing Drivers—Small Molecule Drug Product
Use of Preferred Providers—Small Molecule API
Number of Preferred Providers—Small Molecule API
Use of Preferred Providers—Small Molecule Drug Product
Number of Preferred Providers—Small Molecule Drug Product
Outsourcing Models—Small Molecule API
Outsourcing Models—Small Molecule Drug Product
Outsourced Manufacturing Activities—Small Molecule API
Outsourced Manufacturing Activities—Small Molecule Drug Product
CMO PERCEPTIONS AND INTERACTIONS
Primary Section Takeaways
CMO Familiarity—Small Molecule API
CMO Familiarity—Small Molecule Drug Product
CMO Leaders—Small Molecule API
CMO Leaders—Small Molecule Drug Product
Received Proposals—Small Molecule API
Received Proposals—Small Molecule Drug Product
CMO Use—Small Molecule API
CMO Use—Small Molecule Drug Product
CMO Preference—Small Molecule API
CMO Preference—Small Molecule Drug Product
Summary Table—Small Molecule API
Summary Table—Small Molecule Drug Product
CMO SELECTION DRIVERS
Primary Section Takeaways
CMO Selection Attributes
CMO Selection Attributes Gaining Importance
STUDY DATA
Outsourcing Drivers—Small Molecule API
Outsourcing Drivers—Small Molecule Drug Product
Outsourced Manufacturing Activities—Small Molecule API
Outsourced Manufacturing Activities—Small Molecule Drug Product
Outsourcing Models—Small Molecule API
Outsourcing Models—Small Molecule Drug Product
Use of Preferred Providers—Small Molecule API
Number of Preferred Providers—Small Molecule API
Use of Preferred Providers—Small Molecule Drug Product
Number of Preferred Providers—Small Molecule Drug Product
Top 5 CMO Selection Attributes—Small Molecule API
#1 CMO Selection Attributes—Small Molecule API
Top 5 CMO Selection Attributes—Small Molecule Drug Product
#1 CMO Selection Attributes—Small Molecule Drug Product
CMO Selection Attributes Gaining Importance—Small Molecule API
CMO Selection Attributes Gaining Importance—Small Molecule Drug Product
CMO Familiarity Among Development Outsourcers—Small Molecule API
CMO Familiarity Among Commercial Outsourcers—Small Molecule API
CMO Familiarity Among Development Outsourcers—Small Molecule Drug Product
CMO Familiarity Among Commercial Outsourcers—Small Molecule Drug Product
CMO Leaders—Small Molecule API
To learn more: contact us at [email protected] or +1(919)301-0106
TABLE OF CONTENTS
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
4
CMO Leaders—Small Molecule Drug Product
Received Proposals—Small Molecule API
Received Proposals—Small Molecule Drug Product
CMO Use Among Development Outsourcers—Small Molecule API
CMO Use Among Commercial Outsourcers— Small Molecule API
CMO Use Among Development Outsourcers—Small Molecule Drug Product
CMO Use Among Commercial Outsourcers— Small Molecule Drug Product
CMO Preference—Small Molecule API
CMO Preference—Small Molecule Drug Product
DEMOGRAPHICS
Company Type
Headquarters Location
Office Location
Job Title
Decision-making Responsibility
Contract Manufacturing Responsibilities
Involvement in Outsourced Manufacturing
Years of Industry Experience
ABOUT INDUSTRY STANDARD RESEARCH
To learn more: contact us at [email protected] or +1(919)301-0106
TABLE OF CONTENTS continued
SAMPLE PAGES
84PAGES
84CHARTS
AND GRAPHS
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
5To learn more: contact us at [email protected] or +1(919)301-0106
Development vs Commercial Outsourced Manufacturing Practices: Small Molecule 23www.ISRreports.com ©2017
CMO PERCEPTIONS AND INTERACTIONS
CMO Familiarity—Small Molecule APIThe table below only includes CMOs that >10% of respondents (combined across development and commercial outsourcers) have used. For full data on CMO familiarity, see the Study Data section.
CMO familiarity varies somewhat by outsourcing stage. When it comes to a complete lack of aware-ness, or respondents who indicated they had “never heard of” the company, most CMOs showed parity across the audiences, indicating a broad marketing strategy to increase awareness would benefi t many companies (i.e. those with >30% unaware).
“Please indicate your level of familiarity with each of the following providers of small molecule API manufacturing services?”
Development (n=67) I have used this company's manufacturing
services
I am very familiar with this compa-ny's manufactur-ing services but have not used
them
I am somewhat familiar with
this company's manufacturing
services but have not used them
I am aware of this company
but know noth-ing about its
manufacturing services
I have never heard of this
company Commercial (n=42)
AbbVie Contract Manufacturing
AMRI
Alcami
Almac
Aptuit
Ash Stevens
Cambrex
Dr. Reddy's CPS
Evonik
GSK CMO
Halo Pharma
Lonza
Novasep
Patheon
Pfi zer CentreOne
PharmaCore
Piramal Pharma Solutions 30% 50%
Sanofi CEPiA
Siegfried 46% 26%
Wuxi AppTec
S A M P L E P A G E :
CMO FAMILIARITY—SMALL MOLECULE APIFamiliarity and use data combined with CMO preference statistics can support drug innovators’ CMO selection decision, by knowing which companies their peers have used for different types of projects and how pleased they are with the relationship. CMOs can benefit by understanding which audiences may have awareness gaps and develop marketing strategies to close those gaps.
C L O S E R L O O K :
<< As the table shows, Piramal Pharma Solutions has stronger awareness among development-stage respondents while Siegfried has stronger awareness among commercial respondents.
The full data is available in the report, click here to purchase from ISRreports.com.
D A T A I N F U L L R E P O R T
Development (n=67) I have never heard of this
company Commercial (n=42)
Piramal Pharma Solutions 30% 50%
Siegfried 46% 26%
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
6
34www.ISRreports.com ©2017
CMO PERCEPTIONS AND INTERACTIONS
Development vs Commercial Outsourced Manufacturing Practices: Small Molecule
Summary Table—Small Molecule Drug Product
There is a fair amount of crossover between development-stage and commercial-scale outsourcing re-spondents when it comes to perceived Leadership, Proposal Volume, Use and Preference for small mol-ecule drug product manufacturing.
Development (n=48) Commercial (n=37)
Rank Leadership Proposal Volume Use Preference
1 Company ASanofi CEPiA
2 Company B Company J
3 Company C Company C
4 Company D Company H
5 Company E Company D
6 Company F Company B
7 Company G Company A
8 Company H Company K
9 Company I Company G
10 Company JCompany
L/M/N
S A M P L E P A G E :
SUMMARY TABLE—SMALL MOLECULE DRUG PRODUCTBased on the outsourcing scenario, the same company may have a very different percep-tion among its buying audiences. Sanofi CEPiA takes the #1 rank for perceived leadership among among commercial-scale drug product respondents, but does not appear in the top 10 among respondents outsourcing development-stage drug product manufacturing.
The full data is available in the report, click here to purchase from ISRreports.com.
To learn more: contact us at [email protected] or +1(919)301-0106
D A T A I N F U L L R E P O R T
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
7To learn more: contact us at [email protected] or +1(919)301-0106
39www.ISRreports.com ©2017
CMO SELECTION DRIVERS
Development vs Commercial Outsourced Manufacturing Practices: Small Molecule
CMO Selection Attributes Gaining ImportanceThe table below contains the top three selection attributes for each outsourcing scenario that respondents have indicated are becoming more important when it comes to CMO selection. Again, for comparison and completeness, ranks for attributes that are in the top three for one scenario but not for others are shown in parentheses. Ties are given the average of the ranks they would have received if no scores had tied. Full results for selection attributes gaining in importance can be found in the Study Data section.
Top Three Selection Attributes Gaining Importance by Outsourcing Scenario
Develop-ment-stage
small molecule API
Commer-cial-scale small molecule API
Develop-ment-stage
small molecule drug product
Commer-cial-scale small molecule drug
product
Low cost
Reliable on-time delivery
Strong regulatory track record
Scientifi c knowledge
Up-front contingency planning,risk management
(14) (22) (17) 2.5
• Up-front contingency planning tied for second-third ranks among commercial-scale drug product respondents, but did not make the top 10 among any other respondent group.
• ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
• ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
• -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
• ----------------------------------------------------------------------------------------------------------------------------
S A M P L E P A G E :
SUMMARY TABLE—CMO SELECTION ATTRIBUTES GAINING IMPORTANCEAs the table below shows, a CMO attribute very important to one outsourcing scenario may not be among the top 10 attributes for other outsourcing scenarios.
The full data is available in the report, click here to purchase from ISRreports.com.
D A T A I N F U L L R E P O R T
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
8
To obtain full access to this report, please select one of the following licenses:
To purchase the report with a credit card or invoice, simply click the button below to be taken to the report page. If you’d like to inquire about a different payment method or have questions, contact us at [email protected] or +1.919.301.0106.
To schedule a call to discuss this report with one of our analysts, please e-mail us at [email protected].
ORDERING INFORMATION
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email [email protected], or follow us on twitter @ISRreports.
ABOUT INDUSTRY STANDARD RESEARCH
>> R E G I S T E R N O W>>Receive $250 instant credit towards any ISR report
>>Earn 10% credit towards all future purchases
>>Receive advanced notifications on ISR’s latest reports and free resources
SAVE ON THIS, OR ANY ISR REPORT, BY CREATING A FREE ACCOUNT
SINGLE-USER LICENSE A single-user license allows access to a single individual user. $4,960 USD
SITE-WIDE LICENSE A site-wide license allows access to organization employees within a particular geographic site/location (i.e. NYC or London office).
$7,440 USD
ENTERPRISE-WIDE LICENSE
An enterprise-wide license allows access to ALL employees in an organization – this is the recommended license if a report has widespread relevance throughout an organization.
$9,920 USD
To learn more: contact us at [email protected] or +1(919)301-0106
9
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
TO LEARN MORE: CONTACT US AT [email protected] OR +1(919)301-0106
Biosimilars & Biologics
Clinical Trial Recruitment &
Retention
Commercialization Department Models & Structures
Trends & Technologies
Manufacturing Service Provider Quality Benchmarking
CUSTOM RESEARCH
UNDERSTAND YOUR MARKETSLeverage ISR’s experience and institutional knowledge to create a fit-for-purpose market research project that addresses the business decisions you need to make.
Are you:• Developing a new product or service?• Evaluating a new market?• Targeting a new customer segment?• Entering a new geography?• Needing a deeper understanding of your
customer or potential customer base?
UNDERSTAND YOUR CUSTOMERSWho makes the decisions and in what contexts? ISR can help you gain a deeper understanding of your customers’ decision-making units (DMUs) and decision-making processes (DMPs).
Key Questions Addressed:• What motivates the purchase decision?• How are companies, products, solutions, and/or
brands evaluated?• What factors drive the final buying decision?• Where are your customers won or lost in the
purchasing process?• Why were specific opportunities won or lost?• How do you keep customers engaged and
manage their loyalty over time?
CUSTOM RESEARCH SERVICES• Investigator Forum• Brand, Advertising, and Message Testing• Loyalty Management• New Product and Service Development• Competitive Intelligence• Strategy War Games• MORE
S O M E T H I N G T O C O N S I D E R
DISTINCTIVE – Receive novel insights from industry decision-makers on topics including: service provider quality, patient recruitment, biosimilars, clinical technology, manufacturing, clinical operations, and commercial activities.
UNRESTRICTED – ISR doesn’t sell seats. Instantly obtain access for all employees within your organization
AFFORDABLE – Receive access to ALL reports in ISR’s library, as well as those released during your subscription period. ISR’s competitive library pricing equates to the cost of a few individual report purchases.
LIBRARY ACCESS SUBSCRIPTIONISR’s library access subscription provides your entire organization access to our full library of syndicated market research reports (100+ titles) plus access to all reports (~25 per year) released during your subscription period. Our research categories include:
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
10www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10
act with confidenceTHE ISR DIFFERENCE
Mostly primary research; always appropriate for the topic
One size fits all; usually publically available data
To learn more, visit www.ISRreports.com
ISR’S REPORTS
THECOMMON
SYNDICATEDREPORT
VS.
RESEARCH METHODS
ISR’s proprietary data tools and channelssupport fast, high quality data collection
Struggle to recruit the right targets and enough of them
DATA COLLECTION
Sophisticated screening ensures genuine decision-makers make up respondents
Undisclosed methodologies and respondent demographics
RESPONDENTS
Robust sample sizes that instill confidence
Often insucient industry representationthat leaves you defending results
SAMPLE SIZE
Decades of experience means more insights that are immediately usable
Junior analysts capable of reporting numbers
ANALYSTS
ISR’S HEALTH PANELThe industry’s fastest growing panel of health care and pharmaceutical
professionals, with nearly 1,500 members worldwide.
BYJOB
LEVEL
Director 46%
Manager 29%
C-level 13%
VP 10%
BYEXPERIENCE
IN YEARS
16-20 years 23%
11-15 years 24%
6-10 years 11%
3-5 years 5%
20+ years 37%
BYCOMPANY
TYPE
Other 6%
Sponsor 78%
CRO 6%
ResearchSite 10%
Top Related